Pancreatic Cancer Research

ResearcherVrije Universiteit BrusselActive in the last 2 years

Victor Javier Sanchez-Arevalo Lobo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4561-1505; OpenAlex author ID A5029914236. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
37
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 10

  1. NeoBridge: Biophysics-informed neoantigen prioritization and clonal architecture profiling in pancreatic cancer. Last author DOI 10.1016/j.xgen.2026.101397↗
  2. Molecular subtypes in pancreatic cancer: from academic promise to clinical reality. Last author DOI 10.1186/s12943-026-02614-9↗
  3. Targeting ELOVL6 to disrupt c-MYC driven lipid metabolism in pancreatic cancer enhances chemosensitivity. Last author DOI 10.1038/s41467-025-56894-8↗
  4. The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells. Co-author DOI 10.1136/gutjnl-2023-330995↗
  5. Tumour microenvironment and heterotypic interactions in pancreatic cancer. Last author DOI 10.1007/s13105-022-00875-8↗
  6. Targeting BPTF Sensitizes Pancreatic Ductal Adenocarcinoma to Chemotherapy by Repressing ABC-Transporters and Impairing Multidrug Resistance (MDR). Last author DOI 10.3390/cancers14061518↗
  7. Molecular Alterations in Pancreatic Cancer: Transfer to the Clinic. Last author DOI 10.3390/ijms22042077↗
  8. Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors. First author DOI 10.1158/1535-7163.mct-15-0214↗
  9. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1053/j.gastro.2014.06.041↗
  10. Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer. First author DOI 10.1158/0008-5472.can-12-3359↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ana García García · 4 shared papers, 2021–2025 · strength 0.73
  2. Raúl Muñoz Velasco · 4 shared papers, 2021–2025 · strength 0.73
  3. Elisa Espinet · 2 shared papers, 2024–2026 · strength 0.50
  4. Alejandro Lana Mediavilla · 1 shared paper, 2026 · strength 0.43
  5. Yvan Martineau · 1 shared paper, 2026 · strength 0.36
  6. Daniela M. D'Empaire Altimari · 1 shared paper, 2026 · strength 0.36
  7. Elisa Giovannetti · 1 shared paper, 2026 · strength 0.36
  8. José Luis Rodríguez‐­Peralto · 2 shared papers, 2022–2025 · strength 0.32
  9. Bruno Sáinz · 2 shared papers, 2022–2024 · strength 0.28
  10. Johannes V. Swinnen · 1 shared paper, 2025 · strength 0.18
  11. Yolanda Rodrı́guez Gil · 1 shared paper, 2021 · strength 0.17
  12. Ana García García de Paredes · 1 shared paper, 2024 · strength 0.14
  13. Adrián Palencia‐Campos · 1 shared paper, 2024 · strength 0.14
  14. Sonia Alcalá · 1 shared paper, 2024 · strength 0.14
  15. Susana Garcı́a-Silva · 1 shared paper, 2024 · strength 0.14
  16. Matthias M. Gaida · 1 shared paper, 2024 · strength 0.14
  17. Juan Carlos López-Gil · 1 shared paper, 2024 · strength 0.14
  18. Carmen E. Guerra · 1 shared paper, 2024 · strength 0.14
  19. Alfredo Carrato · 1 shared paper, 2024 · strength 0.14
  20. Christopher Heeschen · 1 shared paper, 2024 · strength 0.14
  21. Jorge Dorado · 1 shared paper, 2024 · strength 0.14
  22. Carolina de la Pinta · 1 shared paper, 2024 · strength 0.14
  23. Julie Earl · 1 shared paper, 2024 · strength 0.14
  24. Francisco X. Real · 3 shared papers, 2013–2016 · strength 0.12
  25. Jose Maria Mazarico · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.